NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kezar Life Sciences, Inc.  (“Kezar” or the “Company”) (NASDAQ: KZR).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Kezar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 28, 2019, pre-market, Kezar announced preliminary data from the first two cohorts of an open-label dose escalation trial of the Company product KZR-616 in patients with systemic lupus erythematosus.  Analysts characterized the trial’s efficacy data as “less than impressive” and noted that two healthy trial volunteers had required hospitalization. 

Following this news, Kezar’s stock price fell $6.99 per share, or 41.39%, to close at $9.90 per share on May 28, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com